Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 898Cyclophosphamide 893fludarabine 517venetoclax 475fludarabine phosphate 464Azacitidine 451Rituximab 418Methotrexate 414Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 284Vincristine 280Daunorubicin 279Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 228Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 203Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 176Radiotherapy 169Prednisone 161Mitoxantrone 160Lenalidomide 159Mercaptopurine 154

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Drug Therapy, Combination × Other hematologic neoplasm × Clear all
NCT00079482 2016-07-21

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
224 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡